iRadimed (NASDAQ:IRMD) CEO Roger Susi Sells 5,000 Shares

iRadimed Corporation (NASDAQ:IRMD) CEO Roger Susi sold 5,000 shares of the stock in a transaction on Monday, January 12th. The shares were sold at an average price of $97.45, for a total value of $487,250.00. Following the completion of the sale, the chief executive officer owned 2,272,500 shares in the company, valued at approximately $221,455,125. The trade was a 0.22% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

iRadimed Trading Up 1.4%

IRMD traded up $1.35 on Tuesday, hitting $99.25. 72,289 shares of the company were exchanged, compared to its average volume of 94,486. The firm has a 50-day moving average price of $93.12 and a two-hundred day moving average price of $77.35. iRadimed Corporation has a twelve month low of $47.48 and a twelve month high of $100.39. The company has a market cap of $1.26 billion, a price-to-earnings ratio of 60.15 and a beta of 1.09.

iRadimed (NASDAQ:IRMD) last posted its quarterly earnings results on Monday, November 3rd. The medical equipment provider reported $0.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.43 by $0.04. The company had revenue of $21.20 million for the quarter, compared to analyst estimates of $20.50 million. iRadimed had a return on equity of 22.93% and a net margin of 26.31%.iRadimed has set its Q4 2025 guidance at 0.470-0.510 EPS and its FY 2025 guidance at 1.840-1.880 EPS. Equities analysts expect that iRadimed Corporation will post 1.66 EPS for the current year.

iRadimed Announces Dividend

The company also recently declared a special dividend, which was paid on Tuesday, December 30th. Investors of record on Wednesday, December 17th were paid a $0.50 dividend. The ex-dividend date was Wednesday, December 17th. iRadimed’s payout ratio is currently 41.21%.

Hedge Funds Weigh In On iRadimed

Large investors have recently bought and sold shares of the stock. CWM LLC grew its holdings in shares of iRadimed by 62.2% during the third quarter. CWM LLC now owns 550 shares of the medical equipment provider’s stock worth $39,000 after purchasing an additional 211 shares during the last quarter. Quarry LP acquired a new stake in shares of iRadimed in the 3rd quarter valued at about $40,000. Tower Research Capital LLC TRC grew its stake in iRadimed by 191.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock worth $45,000 after buying an additional 495 shares during the last quarter. State of Alaska Department of Revenue purchased a new position in iRadimed during the 3rd quarter worth approximately $47,000. Finally, Spire Wealth Management acquired a new position in iRadimed during the second quarter worth approximately $60,000. Institutional investors and hedge funds own 92.34% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on IRMD. Weiss Ratings restated a “buy (b-)” rating on shares of iRadimed in a report on Monday, December 29th. Wall Street Zen lowered iRadimed from a “strong-buy” rating to a “buy” rating in a report on Sunday, October 26th. Roth Capital set a $90.00 price target on iRadimed in a report on Friday, October 31st. Zacks Research upgraded iRadimed to a “hold” rating in a report on Tuesday, November 4th. Finally, Lake Street Capital reissued a “buy” rating and set a $100.00 target price on shares of iRadimed in a research report on Monday, November 3rd. Four research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $87.33.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.